Cathelicidin Evidence Guide
Cathelicidin (LL-37) has solid preclinical data on antimicrobial activity and innate immune modulation, and it is an endogenous human peptide. However, there are no therapeutic clinical trials, systemic delivery is problematic due to rapid degradation, and high concentrations are cytotoxic. Research interest is active but therapeutic translation remains undemonstrated.
Our Take
Cathelicidin (LL-37) has solid preclinical data on antimicrobial activity and innate immune modulation, and it is an endogenous human peptide. However, there are no therapeutic clinical trials, systemic delivery is problematic due to rapid degradation, and high concentrations are cytotoxic. Research interest is active but therapeutic translation remains undemonstrated.
- Evidence context
- Antimicrobial peptide pharmacology, innate immune defense mechanistic research, wound healing models
- Evidence grade
- Level C
- Confidence
- Low
- Reference context
- Reported research reference: No established human therapeutic protocol - topical formulations are in early investigation
Benefits and Evidence
- Antimicrobial Defense: Level C, includes human evidence - Extensive evidence for broad-spectrum activity against bacteria, fungi, and enveloped viruses. Clinical studies link LL-37 deficiency to increased susceptibility to infections.
- Wound Healing: Level C, mostly non-human evidence - Promotes wound closure through stimulation of angiogenesis, keratinocyte migration, and anti-biofilm activity in chronic wound models.
- Inflammatory Modulation: Level C, includes human evidence - LL-37 has context-dependent inflammatory effects: pro-inflammatory during acute infection (beneficial) but may contribute to inflammatory pathology in psoriasis and rosacea.
Side Effects and Warnings
- Potential cytotoxicity to host cells at high concentrations
- May exacerbate inflammatory skin conditions at supraphysiological levels
- Direct peptide administration can cause injection site inflammation
- Vitamin D-mediated induction is generally safe within recommended ranges
- Not approved as a therapeutic agent
- Excess LL-37 is associated with psoriasis and rosacea pathology
- Synthetic LL-37 is expensive to produce and susceptible to degradation
- Systemic administration carries risk of inflammatory side effects
Research Dosage References
- <strong>Topical</strong> - 0.5-5 mg/mL - Once or twice daily - Applied to chronic wounds or skin infections in experimental settings. Formulations with controlled release matrices are under development.
- <strong>Endogenous upregulation</strong> - 2000-5000 IU vitamin D3 - Daily - Vitamin D supplementation increases endogenous LL-37 production. This is the most studied indirect method of enhancing cathelicidin levels.
Mechanism of Action
LL-37 functions through diverse mechanisms: 1. Direct antimicrobial killing: Alpha-helical structure inserts into microbial membranes causing disruption, pore formation, and cell lysis. 2. Endotoxin neutralization: Binds and neutralizes lipopolysaccharide (LPS), preventing septic shock cascade. 3. Immune cell recruitment: Acts as a chemoattractant for neutrophils, monocytes, and T-cells via formyl peptide receptor-like 1 (FPRL1). 4. Vitamin D pathway: Expression is upregulated by 1,25-dihydroxyvitamin D through vitamin D response elements in the CAMP gene promoter. 5. Wound healing promotion: Stimulates angiogenesis and re-epithelialization at wound sites.
Legal Status
LL-37 is a research peptide with no regulatory approval for direct clinical application. Endogenous levels are influenced by several biological factors, including vitamin D signaling.
Primary Sources
- Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol, 2004.
- LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Mol Immunol, 2012.
- The human antimicrobial peptide LL-37 promotes wound healing in vitro and in vivo. J Invest Dermatol, 2003.
Quick Answers
Where is the strongest evidence for Cathelicidin?
Cathelicidin (LL-37) has solid preclinical data on antimicrobial activity and innate immune modulation, and it is an endogenous human peptide. However, there are no therapeutic clinical trials, systemic delivery is problematic due to rapid degradation, and high concentrations are cytotoxic. Research interest is active but therapeutic translation remains undemonstrated. Evidence context: Antimicrobial peptide pharmacology, innate immune defense mechanistic research, wound healing models.
What are the main side effects of Cathelicidin?
Cathelicidin side effects and warning signals include Potential cytotoxicity to host cells at high concentrations, May exacerbate inflammatory skin conditions at supraphysiological levels, Direct peptide administration can cause injection site inflammation, Vitamin D-mediated induction is generally safe within recommended ranges, and Not approved as a therapeutic agent.
What evidence level is Cathelicidin?
Cathelicidin is rated Level C; the listed research status is Preclinical.